Elevai Labs, Inc. Common Stock (ELAB) Filings

SC TO-I/A

Issuer tender offer statement (amended)

4 Nov 24

8-K

Entry into a Material Definitive Agreement

31 Oct 24

8-K

Entry into a Material Definitive Agreement

25 Oct 24

8-K

KNOTUS Co., Ltd. STUDY No. 21 - KE - 1021 Efficacy study of new drug candidate for sarcopenia

24 Oct 24

DEF 14C

Information statement

9 Oct 24

SC TO-I

Issuer tender offer statement

4 Oct 24

8-K

Other Events

2 Oct 24

PRE 14C

Preliminary information

27 Sep 24

8-K

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

25 Sep 24

424B3

Prospectus supplement

24 Sep 24

424B4

Prospectus supplement with pricing info

24 Sep 24

EFFECT

Notice of effectiveness

23 Sep 24

DEFR14C

Revised information

6 Sep 24

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

6 Sep 24

DEF 14C

Information statement

5 Sep 24

8-K

Regulation FD Disclosure

4 Sep 24

8-K

Other Events

26 Aug 24

PRE 14C

Preliminary information

26 Aug 24

PRER14C

Preliminary revised information

23 Aug 24

PRE 14C

Preliminary information

16 Aug 24

PRER14C

Preliminary revised information

16 Aug 24

PRE 14C

Preliminary information

5 Aug 24

8-K

Departure of Directors or Certain Officers

5 Aug 24

8-K

Entry into a Material Definitive Agreement

2 Aug 24

8-K

Regulation FD Disclosure

16 Jul 24

8-K

Entry into a Material Definitive Agreement

12 Jul 24

8-K

Entry into a Material Definitive Agreement

26 Jun 24

8-K

Entry into a Material Definitive Agreement

20 Jun 24

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

24 May 24

8-K

Entry into a Material Definitive Agreement

9 May 24

8-K

Entry into a Material Definitive Agreement

2 May 24

10-K

2023 FY

Annual report

29 Mar 24

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

7 Mar 24

8-K

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

22 Jan 24

10-Q

2023 Q3

Quarterly report

11 Dec 23

SC 13G

S.H.N. Financial Investments Ltd.

2 Oct 24

SC 13G

L1 Capital Global Opportunities Master Fund, Ltd.

1 Oct 24

SC 13G

Altium Capital Management LP

26 Sep 24

SC 13G

MOA LIFE PLUS CO. LTD.

31 May 24

SC 13D

Braeden Lichti

21 Feb 24

3/A

Initial statement of insider ownership (amended)

16 Feb 24

3/A

Lichti Braeden

16 Feb 24

SC 13G

Abou-Sayed Hatem

14 Feb 24

SC 13G

Plews Jordan R.

14 Feb 24

SC 13G

JP Bio Consulting LLC

14 Feb 24

SC 13G

Hatem Abou-Sayed MD MBA FACS, a Professional Medical Corp

14 Feb 24

3

Lichti Braeden

1 Feb 24

4

Change in insider ownership

1 Feb 24

3/A

Initial statement of insider ownership (amended)

1 Feb 24

3

Brenda Beuchler

25 Jan 24

3

Jordan R. Plews

18 Jan 24

3

Initial statement of insider ownership

18 Jan 24

3

Crystal Muilenburg

18 Jan 24

3

Chris Kraneiss

18 Jan 24

3

Juliana Daley

17 Jan 24

3

Jeffrey Parry

17 Jan 24

3

Hatem Abou-Sayed

17 Jan 24

3

Initial statement of insider ownership

17 Jan 24

3

Graydon Bensler

17 Jan 24

3

Initial statement of insider ownership

17 Jan 24

3

Initial statement of insider ownership

17 Jan 24